SERUM AND TISSUE MEASUREMENTS OF CA72-4 IN PATIENTS WITH ENDOMETRIAL CARCINOMA

Aims - To evaluate the clinical usefulness of CA72-4 as a serum tumour marker for endometrial carcinoma and to investigate its immunohistoch emical localisation in endometrial carcinoma cells. Methods-Serum conc entrations of CA72-4 were determined in 72 patients with endometrial c arcinoma. Immunohistochemical localisation of CA72-4 was investigated using the streptavidin-biotin method, using monoclonal antibodies B72. 3 and CC49. Results-Serum CA72-4 was increased above the cut off value in 31.9% of the patients with endometrial carcinoma. Serum CA72-4 pos itivity was correlated with depth of myometrial invasion, adnexal meta stasis, lymphovascular space involvement, and pelvic and para-aortic l ymph node metastasis. Multivariate analysis showed a significant corre lation between serum CA72-4 positivity and adnexal metastasis. The ser um concentrations of CA125 and CA19-9, which could be tumour markers f or endometrial carcinoma, were measured at the same time. In seven of 72 patients increased concentrations of serum CA72-4 were found while those for CA125 and CA19-9 were within the normal ranges; in four of t he seven patients the disease had spread beyond the uterus. Immunohist ochemical positivity for CA72-4 antigen was 76.9% and occurred in the tumour cell membrane and cytoplasm. There was no significant differenc e in immunohistochemical positivity between patients with increased CA 72-4 and those with normal CA72-4 values. Conclusions-The measurement of serum concentrations of CA 72-4 could be useful for predicting and monitoring the progress of disease-for example, extra-corporeal spread .